The cyclins: A family of widely expressed tumor antigens?

Expert Review of Vaccines

Volumn 10, Issue 3, 2011, Pages 389-395

  Von Bergwelt Baildon, Michael S ^a,b   Kondo, Eisei ^c   Klein Gonźlez, Nela ^a   Wendtner, Clemens M ^b  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

^c OKAYAMA UNIVERSITY HOSPITAL   (Japan)

Author keywords

active immunotherapy; cyclin; T cell epitopes; tumor antigens

Indexed keywords

CANCER VACCINE; CYCLIN A1; CYCLIN A2; CYCLIN B; CYCLIN C; CYCLIN D1; CYCLIN D2; CYCLIN D3; CYCLIN DEPENDENT KINASE; CYCLIN E; CYCLIN F; CYCLINE; HLA A ANTIGEN; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; PROTEIN P53; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ACTIVE IMMUNIZATION; ADVANCED CANCER; ANTIGEN EXPRESSION; CANCER GROWTH; CANCER THERAPY; CELL CYCLE PHASE; CELL CYCLE REGULATION; CELL EXPANSION; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; HUMAN; IMMUNE SYSTEM; NEOPLASM; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; REVIEW;

ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; CELL CYCLE; CELL DIVISION; CLINICAL TRIALS AS TOPIC; CYCLINS; EPITOPES, T-LYMPHOCYTE; HUMANS; IMMUNOTHERAPY; MICE; NEOPLASMS;

EID: 79953241925     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.10.170     Document Type: Review

References (88)

1. Sadovnikova E, Jopling LA, Soo KS, Stauss HJ. Generation of human tumor-reactive cytotoxic T cells against peptides presented by non-self HLA class I molecules. Eur. J. Immunol. 28(1), 193-200 (1998). Excellent example of the generation of cytotoxic T cells specific for a widely expressed protein from MHC-mismatched donors to circumvent T-cell tolerance.
2. Hunter T, Pines J. Cyclins and cancer. Cell 66(6), 1071-1074 (1991).
3. Zhou P, Jiang W, Zhang YJ et al. Antisense to cyclin D1 inhibits growth and reverses the transformed phenotype of human esophageal cancer cells. Oncogene 11(3), 571-580 (1995).
4. Li K, Lin SY, Brunicardi FC, Seu P. Use of RNA interference to target cyclin E-overexpressing hepatocellular carcinoma. Cancer Res. 63(13), 3593-3597 (2003).
5. De Falco M, De Luca A. Cell cycle as a target of antineoplastic drugs. Curr. Pharm. Des. 16(12), 1417-1426 (2010).
6. Wang RF, Wang X, Atwood AC, Topalian SL, Rosenberg SA. Cloning genes encoding MHC class II-restricted antigens: mutated CDC27 as a tumor antigen. Science 284(5418), 1351-1354 (1999).
7. Wolfel T, Hauer M, Schneider J et al. A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 269(5228), 1281-1284 (1995).
8. Kao H, Marto JA, Hoffmann TK et al. Identification of Cyclin B1 as a shared human epithelial tumor-associated antigen recognized by T cells. J. Exp. Med. 194(9), 1313-1324 (2001). Excellently describes the identification of cyclin B1 as a tumor antigen.
9. Dahl AM, Beverley PC, Stauss HJ. A synthetic peptide derived from the tumor-associated protein mdm2 can stimulate autoreactive, high avidity cytotoxic T lymphocytes that recognize naturally processed protein. J. Immunol. 157(1), 239-246 (1996).
10. Kolb HJ, Mittermuller J, Clemm C et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 76(12), 2462-2465 (1990).
11. Small EJ, Schellhammer PF, Higano CS et al. Placebo-controlled Phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J. Clin. Oncol. 24(19), 3089-3094 (2006). Provenge (Sipuleucel-T) is the first US FDA-approved cancer immunotherapy.
12. Rosenberg SA, Dudley ME. Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr. Opin. Immunol. 21(2), 233-240 (2009). Excellently reviews how the authors have developed adoptive immunotherapy against melanoma and describes future prospects of the therapies.
13. Cheever MA, Allison JP, Ferris AS et al. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin. Cancer Res. 15(17), 5323-5337 (2009). Excellently describes development of criteria for the ideal tumor antigen.
14. Oka Y, Sugiyama H. WT1 peptide vaccine, one of the most promising cancer vaccines: its present status and the future prospects. Immunotherapy 2(5), 591-594 (2010).
15. Gao L, Yang TH, Tourdot S, Sadovnikova E, Hasserjian R, Stauss HJ. Allo-major histocompatibility complex-restricted cytotoxic T lymphocytes engraft in bone marrow transplant recipients without causing graft-versus-host disease. Blood 94(9), 2999-3006 (1999). Cyclin D1-specific cellular immunity can be induced in an autologous setting.
16. Kondo E, Maecker B, Weihrauch M et al. Cyclin D1-specific cytotoxic T lymphocytes are present in the repertoire of cancer patients: implications for cancer immunotherapy. Clin. Cancer Res. 14(20), 6574-6579 (2008).
17. Wang M, Sun L, Qian J et al. Cyclin D1 as a universally expressed mantle cell lymphoma-associated tumor antigen for immunotherapy. Leukemia 23(7), 1320-1328 (2009).
18. Volm M, Koomagi R, Mattern J, Stammler G. Cyclin A is associated with an unfavourable outcome in patients with non-small-cell lung carcinomas. Br. J. Cancer 75(12), 1774-1778 (1997).
19. Kuhling H, Alm P, Olsson H et al. Expression of cyclins E, A, and B, and prognosis in lymph node-negative breast cancer. J. Pathol. 199(4), 424-431 (2003).
20. Ohashi R, Gao C, Miyazaki M et al. Enhanced expression of cyclin E and cyclin A in human hepatocellular carcinomas. Anticancer Res. 21(1B), 657-662 (2001).
21. Renshaw AA, Loughlin KR, Dutta A. Cyclin A and MIB1 (Ki67) as markers of proliferative activity in primary renal neoplasms. Mod. Pathol. 11(10), 963-966 (1998).
22. Michalides R, van Tinteren H, Balkenende A et al. Cyclin A is a prognostic indicator in early stage breast cancer with and without tamoxifen treatment. Br. J. Cancer 86(3), 402-408 (2002).
23. Dobashi Y, Shoji M, Jiang SX, Kobayashi M, Kawakubo Y, Kameya T. Active cyclin A-CDK2 complex, a possible critical factor for cell proliferation in human primary lung carcinomas. Am. J. Pathol. 153(3), 963-972 (1998).
24. Handa K, Yamakawa M, Takeda H, Kimura S, Takahashi T. Expression of cell cycle markers in colorectal carcinoma: superiority of cyclin A as an indicator of poor prognosis. Int. J. Cancer 84(3), 225-233 (1999).
25. Kondo E, Maecker B, Draube A et al. The shared tumor associated antigen cyclin-A2 is recognized by high-avidity T-cells. Int. J. Cancer 125(10), 2474-2478 (2009).
26. Yang R, Nakamaki T, Lübbert M et al. Cyclin A1 expression in leukemia and normal hematopoietic cells. Blood 93(6), 2067-2074 (1999).
27. Holm C, Ora I, Brunhoff C, Anagnostaki L, Landberg G, Persson JL. Cyclin A1 expression and associations with disease characteristics in childhood acute lymphoblastic leukemia. Leuk. Res. 30(3), 254-261 (2006).
28. Muller-Tidow C, Diederichs S, Schrader MG et al. Cyclin A1 is highly expressed in aggressive testicular germ cell tumors. Cancer Lett. 190(1), 89-95 (2003).
29. Kondo E, Gryschok L, Schultze JL, von Bergwelt-Baildon MS. Using CD40-activated B cells to efficiently identify epitopes of tumor antigens. J. Immunother. 32(2), 157-160 (2009).
30. Hassan KA, El-Naggar AK, Soria JC, Liu D, Hong WK, Mao L. Clinical significance of cyclin B1 protein expression in squamous cell carcinoma of the tongue. Clin. Cancer Res. 7(8), 2458-2462 (2001).
31. Wang A, Yoshimi N, Ino N, Tanaka T, Mori H. Overexpression of cyclin B1 in human colorectal cancers. J. Cancer Res. Clin. Oncol. 123(2), 124-127 (1997).
32. Soria JC, Jang SJ, Khuri FR et al. Overexpression of cyclin B1 in early-stage non-small cell lung cancer and its clinical implication. Cancer Res. 60(15), 4000-4004 (2000).
33. El-Ghobashy AA, Shaaban AM, Herod J, Innes J, Prime W, Herrington CS. Overexpression of cyclins A and B as markers of neoplastic glandular lesions of the cervix. Gynecol. Oncol. 92(2), 628-634 (2004).
34. Nozoe T, Korenaga D, Kabashima A, Ohga T, Saeki H, Sugimachi K. Significance of cyclin B1 expression as an independent prognostic indicator of patients with squamous cell carcinoma of the esophagus. Clin. Cancer Res. 8(3), 817-822 (2002).
35. Song Y, Zhao C, Dong L et al. Overexpression of cyclin B1 in human esophageal squamous cell carcinoma cells induces tumor cell invasive growth and metastasis. Carcinogenesis 29(2), 307-315 (2008).
36. Takeno S, Noguchi T, Kikuchi R, Uchida Y, Yokoyama S, Muller W. Prognostic value of cyclin B1 in patients with esophageal squamous cell carcinoma. Cancer 94(11), 2874-2881 (2002).
37. Dong Y, Sui L, Watanabe Y, Sugimoto K, Tokuda M. Clinical relevance of cyclin B1 overexpression in laryngeal squamous cell carcinoma. Cancer Lett. 177(1), 13-19 (2002).
38. Covini G, Chan EK, Nishioka M, Morshed SA, Reed SI, Tan EM. Immune response to cyclin B1 in hepatocellular carcinoma. Hepatology 25(1), 75-80 (1997).
39. Suzuki H, Graziano DF, McKolanis J, Finn OJ. T cell-dependent antibody responses against aberrantly expressed cyclin B1 protein in patients with cancer and premalignant disease. Clin. Cancer Res. 11(4), 1521-1526 (2005).
40. Koziol JA, Zhang JY, Casiano CA et al. Recursive partitioning as an approach to selection of immune markers for tumor diagnosis. Clin. Cancer Res. 9(14), 5120-5126 (2003).
41. Sorensen RB, Andersen RS, Svane IM et al. CD8 T-cell responses against cyclin B1 in breast cancer patients with tumors overexpressing p53. Clin. Cancer Res. 15(5), 1543-1549 (2009).
42. Vella LA, Yu M, Fuhrmann SR, El-Amine M, Epperson DE, Finn OJ. Healthy individuals have T-cell and antibody responses to the tumor antigen cyclin B1 that when elicited in mice protect from cancer. Proc. Natl Acad. Sci. USA 106(33), 14010-14015 (2009).
43. von Bergwelt-Baildon MS. Biological and biotechnological analysis of CD40-activated B cells and antigen presenting cells. von Ossietzky C (Ed.). Universität Oldenburg, Germany (2003).
44. Andersen RS, Sorensen RB, Ritter C et al. Identification of a cyclin B1-derived CTL epitope eliciting spontaneous responses in both cancer patients and healthy donors. Cancer Immunol. Immunother. 60(2) 227-234 (2010).
45. Park SH, Yu GR, Kim WH, Moon WS, Kim JH, Kim DG. NF-Y-dependent cyclin B2 expression in colorectal adenocarcinoma. Clin. Cancer Res. 13(3), 858-867 (2007).
46. Hofmann HS, Hansen G, Burdach S, Bartling B, Silber RE, Simm A. Discrimination of human lung neoplasm from normal lung by two target genes. Am. J. Respir. Crit. Care Med. 170(5), 516-519 (2004).
47. Hernandez J, Lee PP, Davis MM, Sherman LA. The use of HLA A2.1/p53 peptide tetramers to visualize the impact of self tolerance on the TCR repertoire. J. Immunol. 164(2), 596-602 (2000).
48. Muller H, Lukas J, Schneider A et al. Cyclin D1 expression is regulated by the retinoblastoma protein. Proc. Natl Acad. Sci. USA 91(8), 2945-2949 (1994).
49. Ratschiller D, Heighway J, Gugger M et al. Cyclin D1 overexpression in bronchial epithelia of patients with lung cancer is associated with smoking and predicts survival. J. Clin. Oncol. 21(11), 2085-2093 (2003).
50. Arber N, Hibshoosh H, Moss SF et al. Increased expression of cyclin D1 is an early event in multistage colorectal carcinogenesis. Gastroenterology 110(3), 669-674 (1996).
51. Arber N, Gammon MD, Hibshoosh H et al. Overexpression of cyclin D1 occurs in both squamous carcinomas and adenocarcinomas of the esophagus and in adenocarcinomas of the stomach. Hum. Pathol. 30(9), 1087-1092 (1999).
52. Weinschenk T, Gouttefangeas C, Schirle M et al. Integrated functional genomics approach for the design of patient-individual antitumor vaccines. Cancer Res. 62(20), 5818-5827 (2002).
53. Dengjel J, Decker P, Schoor O et al. Identification of a naturally processed cyclin D1 T-helper epitope by a novel combination of HLA class II targeting and differential mass spectrometry. Eur. J. Immunol. 34(12), 3644-3651 (2004). Excellently describes a novel approach for identifying naturally processed and presented peptides derived from chosen antigens by mass spectrometry.
54. Barnes DM, Gillett CE. Cyclin D1 in breast cancer. Breast Cancer Res. Treat. 52(1-3), 1-15 (1998).
55. Al-Aynati MM, Radulovich N, Ho J, Tsao MS. Overexpression of G1-S cyclins and cyclin-dependent kinases during multistage human pancreatic duct cell carcinogenesis. Clin. Cancer Res. 10(19), 6598-6605 (2004).
56. Nakamura S, Yatabe Y, Seto M. Cyclin D1 overexpression in malignant lymphomas. Pathol. Int. 47(7), 421-429 (1997).
57. Han EK, Lim JT, Arber N, Rubin MA, Xing WQ, Weinstein IB. Cyclin D1 expression in human prostate carcinoma cell lines and primary tumors. Prostate 35(2), 95-101 (1998).
58. Dao T, Korontsvit T, Zakhaleva V, Haro K, Packin J, Scheinberg DA. Identification of a human cyclin D1-derived peptide that induces human cytotoxic CD4 T cells. PLoS ONE 4(8), e6730 (2009).
59. Shi FD, Zhang JY, Liu D et al. Preferential humoral immune response in prostate cancer to cellular proteins p90 and p62 in a panel of tumor-associated antigens. Prostate 63(3), 252-258 (2005). Excellently reviews cyclin A and cyclin E overexpression in various cancers and its association with prognosis.
60. Takano Y, Kato Y, Masuda M, Ohshima Y, Okayasu I. Cyclin D2, but not cyclin D1, overexpression closely correlates with gastric cancer progression and prognosis. J. Pathol. 189(2), 194-200 (1999).
61. Faussillon M, Monnier L, Junien C, Jeanpierre C. Frequent overexpression of cyclin D2/cyclin-dependent kinase 4 in Wilms' tumor. Cancer Lett. 221(1), 67-75 (2005).
62. Watson DS, Brotherick I, Shenton BK et al. Cyclin D3 expression, cell proliferation and pathological stage of human primary colorectal cancer. Oncology, 56(1), 66-72 (1999).
63. Hedberg Y, Roos G, Ljungberg B, Landberg G. Cyclin D3 protein content in human renal cell carcinoma in relation to cyclin D1 and clinico-pathological parameters. Acta. Oncol. 41(2), 175-181 (2002).
64. Li H, Lahti JM, Valentine M et al. Molecular cloning and chromosomal localization of the human cyclin C (CCNC) and cyclin E (CCNE) genes: deletion of the CCNC gene in human tumors. Genomics 32(2), 253-259 (1996).
65. Ohata N, Ito S, Yoshida A et al. Highly frequent allelic loss of chromosome 6q16-23 in osteosarcoma: involvement of cyclin C in osteosarcoma. Int. J. Mol. Med. 18(6), 1153-1158 (2006).
66. Galamb O, Sipos F, Molnar B, Szoke D, Spisak S, Tulassay Z. Evaluation of malignant and benign gastric biopsy specimens by mRNA expression profile and multivariate statistical methods. Cytometry B Clin. Cytom. 72(5), 299-309 (2007).
67. Husdal A, Bukholm G, Bukholm IR. The prognostic value and overexpression of cyclin A is correlated with gene amplification of both cyclin A and cyclin E in breast cancer patient. Cell. Oncol. 28(3), 107-116 (2006).
68. Bondi J, Husdal A, Bukholm G, Nesland JM, Bakka A, Bukholm IR. Expression and gene amplification of primary (A, B1, D1, D3, and E) and secondary (C and H) cyclins in colon adenocarcinomas and correlation with patient outcome. J. Clin. Pathol. 58(5), 509-514 (2005).
69. Yasmeen A, Berdel WE, Serve H, Müller-Tidow C. E- and A-type cyclins as markers for cancer diagnosis and prognosis. Expert Rev. Mol. Diagn. 3(5), 617-633 (2003).
70. Guo X, Wu Y, Hartley RS. Cold-inducible RNA-binding protein contributes to human antigen R and cyclin E1 deregulation in breast cancer. Mol. Carcinog. 49(2), 130-140 (2010).
71. Finn OJ. Immunological weapons acquired early in life win battles with cancer late in life. J. Immunol. 181(3), 1589-1592 (2008).
72. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat. Med. 10(9), 909-915 (2004).
73. Steinman RM, Banchereau J. Taking dendritic cells into medicine. Nature 449(7161), 419-426 (2007).
74. Nagorsen D, Thiel E. Clinical and immunologic responses to active specific cancer vaccines in human colorectal cancer. Clin. Cancer Res. 12(10), 3064-3069 (2006).
75. Steinman RM, Hawiger D, Nussenzweig MC. Tolerogenic dendritic cells. Annu. Rev. Immunol. 21, 685-711 (2003).
76. Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat. Rev. Immunol. 6(4), 295-307 (2006).
77. Gabrilovich D. Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat. Rev. Immunol. 4(12), 941-952 (2004).
78. Chang MH, You SL, Chen CJ et al. Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study. J. Natl Cancer Inst. 101(19), 1348-1355 (2009).
79. Kahn JA. HPV vaccination for the prevention of cervical intraepithelial neoplasia. N. Engl. J. Med. 361(3), 271-278 (2009).
80. Tsui IF, Poh CF, Garnis C, Rosin MP, Zhang L, Lam WL. Multiple pathways in the FGF signaling network are frequently deregulated by gene amplification in oral dysplasias. Int. J. Cancer 125(9), 2219-2228 (2009).
81. Bergsagel PL, Kuehl WM, Zhan F, Sawyer J, Barlogie B, Shaughnessy J. Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood 106(1), 296-303 (2005).
82. Rasmussen T, Kuehl M, Lodahl M, Johnsen HE, Dahl IM. Possible roles for activating RAS mutations in the MGUS to MM transition and in the intramedullary to extramedullary transition in some plasma cell tumors. Blood 105(1), 317-323 (2005).
83. Horree N, Heintz AP, Sie-Go DM, van Diest PJ. p16 is consistently expressed in endometrial tubal metaplasia. Cell. Oncol. 29(1), 37-45 (2007).
84. Shukla S, Gupta S. Apigenin-induced cell cycle arrest is mediated by modulation of MAPK, PI3K-Akt, and loss of cyclin D1 associated retinoblastoma dephosphorylation in human prostate cancer cells. Cell Cycle 6(9), 1102-1114 (2007).
85. Shukla S, Gupta S. Molecular targets for apigenin-induced cell cycle arrest and apoptosis in prostate cancer cell xenograft. Mol. Cancer Ther. 5(4), 843-852 (2006).
86. Yedjou CG, Tchounwou PB. Modulation of p53, c-fos, RARE, cyclin A, and cyclin D1 expression in human leukemia (HL-60) cells exposed to arsenic trioxide. Mol. Cell. Biochem. 331(1-2), 207-214 (2009).
87. Leisenfelder SA, Moffat JF. Varicella-zoster virus infection of human foreskin fibroblast cells results in atypical cyclin expression and cyclin-dependent kinase activity. J. Virol. 80(11), 5577-5587 (2006).
88. Cancer immunome database http://ludwig-sun5.unil.ch/CancerImmunomeDB/